Drugs / 177Lu-IM-3050
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07505771 | Jun 2026 → Dec 2029 expected | cancer | Immunome, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-IM-3050 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07505771 ↗ |
| Route | Intravenous | “177Lu-IM-3050 administered intravenously on a 6-week cycle” NCT07505771 ↗ |